Cardiac biomarkers in patients with chronic kidney disease

  • Research type

    Research Study

  • Full title

    Cardiac biomarkers in patients with chronic kidney disease: biological variation and prognostic usefulness in patients with stable G3 chronic kidney disease The eGFR-C Study.

  • IRAS ID

    224008

  • Contact name

    Edmund J Lamb

  • Contact email

    elamb@nhs.net

  • Sponsor organisation

    East Kent Hospitals University NHS Foundation Trust

  • ISRCTN Number

    ISRCTN42955626

  • Clinicaltrials.gov Identifier

    NCT02433002

  • Clinicaltrials.gov Identifier

    135229, IRAS ref no.; HTA 11/103/01, HTA ref no.

  • Duration of Study in the UK

    4 years, 0 months, 1 days

  • Research summary

    Cardiac (heart) markers are used to diagnose heart attacks. Patients with kidney disease are at increased risk of cardiac events.
    Patients with kidney disease commonly have increased heart markers, including a protein called troponin, in the absence of having suffered a heart attack. This creates a diagnostic difficulty. If we can better understand how much heart marker concentrations normally vary by in the blood of kidney patients, it will be easier to detect when true heart attacks are occurring. To date, this area has not been researched. Furthermore, although raised heart markers are known to predict death in patients with kidney disease, it is not known whether the raised concentrations of heart markers also predict worsening of patient’s kidney disease.
    Previously it would have been difficult to answer these research questions due to technological limitations (poor sensitivity) of the tests. Recently new versions of these tests have become available, enabling accurate measurements in the blood of people who haven’t had a heart attack. Now these new tests are available, we will be able to measure the markers in patients with kidney disease and answer questions about the natural biological variability of the markers and whether they predict progressive kidney disease.
    We have suitable stored blood samples available as part of the large eGFR-C study we have been conducting. Participants in this study have given consent for their samples to be used for further research purposes, including heart marker measurements, providing that such future studies have ethical approval.

  • REC name

    London - City & East Research Ethics Committee

  • REC reference

    17/LO/0707

  • Date of REC Opinion

    19 Apr 2017

  • REC opinion

    Favourable Opinion